Consequences on economic outcomes of generic versus brand-name drugs used in routine clinical practice: the case of treating peripheral neuropathic pain or generalized anxiety disorder with pregabalin-Reference-Cited by-同舟云学术

Consequences on economic outcomes of generic versus brand-name drugs used in routine clinical practice: the case of treating peripheral neuropathic pain or generalized anxiety disorder with pregabalin

Published:2018-09-17 Issue:1 Volume:19 Page:45-57
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Sicras-Mainar Antoni¹,Rejas-Gutiérrez Javier²,Pérez-Paramo María³,Sánchez-Alvarez Luis⁴,Navarro-Artieda Ruth⁵,Darbà Josep⁶

Affiliation:

1. Scientific Directorate, ClinicResearch, Tiana, Barcelona, Spain

2. Health Economics and Outcomes Research Department, Pfizer, SLU, Alcobendas, Spain

3. Medical Department, Pfizer GEP SLU, Alcobendas, Spain

4. Primary Care Pharmacy Directorate, Avilés Primary Care Center, Avilés, Spain

5. Department of Medical Documentation, Hospital Germans Trias i Pujol, Badalona, Spain

6. Department of Economics, Universitat de Barcelona, Barcelona, Spain

Funder

Pfizer S.L.U

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2019.1519399

Reference53 articles.

1. Interventional management of neuropathic pain: NeuPSIG recommendations

2. Neuropathic pain in the general population: A systematic review of epidemiological studies

3. The prevalence and burden of subthreshold generalized anxiety disorder: a systematic review

4. The burden of neuropathic pain: A systematic review and meta-analysis of health utilities

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Curative care expenditure of outpatient anxiety disorder in Liaoning Province, 2015-2020-based on “System of Health Accounts 2011”;Frontiers in Public Health;2024-07-03

2. Overall clinical and economic impact of non-alcoholic fatty liver disease;Revista Española de Enfermedades Digestivas;2020